Optimum Use of Second Line Treatment Options for Erectile Dysfunction
About 30 % of patients receiving PDE5-Inhibitors for the treatment of erectile dysfunction do not respond to oral drug. It could depend on lack of correct information for drug use, lack of appropriate follow-up, presence of comorbidities, unrealistic patient expectations, incorrect diagnosis, performance anxiety and problematic relationships. So, before prescribing to patients a second line therapy, it is mandatory to carefully check if patient is taking PDE5-inhibitors in the right way and with an adequate sexual stimulation, if the medication taken is a licensed one, if patient is affected by hypogonadism and therefore needs a testosterone replacement therapy or if patient could benefit from the treatment of comorbidities. In addition, switching to another PDE5-inhibitor or a combination therapy with long-acting and short-acting PDE5-inhibitors could be effective strategies in non-responders. If patients are still not-responders, a second line therapy could be suggested. Intracavernosal injections (ICI) with vasoactive agents (prostaglandins, papaverine, phentolamine, vasoactive intestinal polypeptide) are the most widely used second line therapy and their effectiveness is high (>70 %). Nevertheless, the drop-out rate of these therapy is still high due to willing of a definitive and permanent therapy, discomfort in self-injection, lack of spontaneity in sexual relationship and stop of sexual activity. Use of vacuum device is a valid treatment too for erectile dysfunction with a success rate of more than 90 % and could be an alternative method in older patients in a stable relationship. Treatment with alprostadil cream with a permeation enhancer in patients affected by erectile dysfunction of all etiology and physical therapy with low-intensity shockwave in patients affected by vasculogenic erectile dysfunction are very promising strategies but to date no specific recommendation could be given for their use. Combination of different second line therapies or combination between a second line treatment and a PDE5-inhibitor could be tried before proposing a penile prosthesis implant.
KeywordsErectile dysfunction Second line therapy
- 1.Feldman HA, Goldstein I, Hatzichristou DG, Krane RJ, McKinlay JB. Impotence and its medical and psychosocial correlates: results of the Massachusetts Male Aging Study. J Urol. 1994;151(1):54–61.Google Scholar
- 4.Mirone V, Gentile V, Zizzo G, Terry M, Longo N, Fusco F, Parazzini F. Did men with erectile dysfunction discuss their condition with partner and physicians? A survey of men attending a free call information service. Int J Impot Res. 2002;14(4):256–8.Google Scholar
- 14.Buvat J, Montorsi F, Maggi M, Porst H, Kaipia A, Colson MH, Cuzin B, Moncada I, Martin-Morales A, Yassin A, Meuleman E, Eardley I, Dean JD, Shabsigh R. Hypogonadal men nonresponders to the PDE5 inhibitor tadalafil benefit from normalization of testosterone levels with a 1 % hydroalcoholic testosterone gel in the treatment of erectile dysfunction (TADTEST study). J Sex Med. 2011;8(1):284–93.CrossRefPubMedGoogle Scholar
- 15.Eardley I, et al. Factors associated with preference for sildenafil citrate and tadalafil for treating erectile dysfunction in men naive to phosphodiesterase 5 inhibitor therapy: post hoc analysis of data from a multicentre, randomized, open-label, crossover study. BJU Int. 2007;100(1):122–9.CrossRefPubMedGoogle Scholar
- 20.Molderings GJ, van Ahlen H, Gothert M. Modulation of noradrenaline release in human corpus cavernosum by presynaptic prostaglandin receptors. Int J Impot Res. 1992;4:19–25.Google Scholar